ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049

Its studies are mostly in Colorectal Neoplasms, led by Boehringer Ingelheim.

Drug pageAnti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Feb 11, 20213 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim30 open or runningphase 1since Feb 11, 2021Feb 11, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2021First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT04752215 · 67 enrolled · United States, Canada
  2. Oct 16, 2023Phase 1 study in Gastrointestinal NeoplasmsNCT06091930 · 21 enrolled · Japan
  3. Mar 17, 2025Phase 1 study in Colorectal NeoplasmsNCT06882746 · 14 enrolled · United States, Germany, Spain

TargetBeta

“An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06882746Colorectal Neoplasms · United States, Germany, Spain1TerminatedSep 8, 202614
NCT06091930Gastrointestinal Neoplasms · Japan1TerminatedAug 15, 202521
NCT04752215Colorectal Neoplasms · United States, Canada1CompletedNov 19, 202467

How it is read

Names in the registry

  • “BI 765049”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.